Upadacitinib hemihydrate is a medication, specifically a Janus kinase (JAK) inhibitor, used to treat various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis. It’s a small molecule drug, and its hemihydrate form indicates it contains half a molecule of water per molecule of upadacitinib. It is grouped under the following drug class(es): Kinase inhibitors. Its therapeutic use is listed as antirheumatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include NEW4DV02U5, bis(upadacitinib) hydrate and Rinvoq (TN). Its PubChem CID is 133053456.
Upadacitinib hemihydrate
| CAS No | 2050057-56-0 |
|---|---|
| Molecular Formula | C34H40F6N12O3 |
| Molecular Weight | 778.80 g/mol |
| Synonyms | bis((3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide);hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Upadacitinib hemihydrate is a medication, specifically a Janus kinase (JAK) inhibitor, used to treat various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis.
The listed CAS number is 2050057-56-0.
The listed molecular formula is C34H40F6N12O3.
The listed molecular weight is 778.80 g/mol.
bis((3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide);hydrate.
The source lists NEW4DV02U5, bis(upadacitinib) hydrate and Rinvoq (TN).